Compagnie Financiere Richemont S.A. ADS (CFRUY) Financials
Compagnie Financiere Richemont S.A. ADS (CFRUY) Financials Nov 14, 2014, 8:10 p.m.
Income Statement Balance Sheet Cash Flow Statement
Annual Financials for Compagnie Financiere Richemont S.A. ADS
Fiscal year is April-March. All values CHF millions. 2010 2011 2012 2013 2014 5-year trend
Sales/Revenue 7.77B 9.22B 10.75B 12.28B 13.09B
Cost of Goods Sold (COGS) incl. D&A 3B 3.42B 3.98B 4.47B 4.88B
COGS excluding D&A 2.65B 3.04B 3.57B 4.01B 4.35B
Depreciation & Amortization Expense 349.76M 386.74M 402.63M 463.38M 529.99M
Depreciation 271.7M 282.36M 299.54M 356.91M 419.32M
Amortization of Intangibles 78.06M 104.38M 103.08M 106.47M 110.67M
Gross Income 4.77B 5.8B 6.78B 7.81B 8.22B
2010 2011 2012 2013 2014 5-year trend
SG&A Expense 3.45B 4B 4.29B 4.91B 5.26B
Research & Development 34.53M 44.16M 64.27M 66.54M 65.17M
Other SG&A 3.41B 3.95B 4.23B 4.84B 5.19B
Other Operating Expense 54.04M 8.03M 27.89M 1.21M 0
Unusual Expense 39.03M (91M) 67.91M 93.16M (266.84M)
EBIT after Unusual Expense (39.03M) 91M (67.91M) (93.16M) 266.84M
Non Operating Income/Expense (171.13M) (303.77M) (194.04M) 96.79M (140.18M)
Non-Operating Interest Income 22.52M 22.75M 37.59M 20.57M 19.67M
Equity in Affiliates (Pretax) 0 - - - -
Interest Expense 39.03M 36.13M 36.38M 45.98M 56.57M
Gross Interest Expense 39.03M 36.13M 36.38M 45.98M 56.57M
Interest Capitalized 0 0 0 0 0
Pretax Income 1.04B 1.57B 2.2B 2.88B 3.05B
Income Tax 141.1M 262.29M 320.16M 447.65M 505.4M
Income Tax - Current Domestic 193.64M 305.11M 426.88M 399.26M 534.91M
Income Tax - Current Foreign - - - - -
Income Tax - Deferred Domestic (52.54M) (42.82M) (106.72M) 48.39M (29.51M)
Income Tax - Deferred Foreign - - - - -
Income Tax Credits 0 0 0 0 0
Equity in Affiliates 6M 135.16M (10.91M) (4.84M) (6.15M)
Other After Tax Income (Expense) 0 0 0 0 0
Consolidated Net Income 905.16M 1.44B 1.87B 2.43B 2.54B
Minority Interest Expense 1.5M (14.72M) (4.85M) (9.68M) (6.15M)
Net Income 903.66M 1.46B 1.87B 2.44B 2.55B
Extraordinaries & Discontinued Operations (4.5M) 0 0 0 0
Extra Items & Gain/Loss Sale Of Assets 0 0 0 0 0
Cumulative Effect - Accounting Chg 0 0 0 0 0
Discontinued Operations (4.5M) 0 0 0 0
Net Income After Extraordinaries 899.16M 1.46B 1.87B 2.44B 2.55B
Preferred Dividends 0 0 0 0 0
Net Income Available to Common 903.66M 1.46B 1.87B 2.44B 2.55B
EPS (Basic) 1.63 2.65 3.42 4.43 4.56
Basic Shares Outstanding 553M 551.3M 548.3M 550.1M 558.4M
EPS (Diluted) 1.61 2.58 3.34 4.35 4.52
Diluted Shares Outstanding 559.5M 566.1M 560.2M 560M 563.6M
EBITDA 1.62B 2.18B 2.86B 3.36B 3.49B
Copyright 2014 FactSet Research Systems Inc. All rights reserved. Source FactSet Fundamentals.
Scroll down for more posts ▼
Top 10 Most Recent News Articles
High Stakes and Deep Insights Await in Houston Cracking the nut of lower-middle market transactions ain’t a walk in the park. M&A Source®'s Fall 2026 Conference is gearing up to address the very dramas that lurk behind the scenes. Kicking off November 2-4 at the opulent JW Marriott in Houston, Texas, the event is looking to assemble a heavyweight lineup of...
Continue Reading
A Mess That Investors Can't Ignore If you're holding onto Endava plc shares, you've probably felt that gut-punch lately. Yeah, things are getting heated with a class action lawsuit alleging the company played fast and loose with its accounting practices. The complaint's about some shady dealings that may have thrown off investors' perceptions. The Core Allegations This...
Continue Reading
Big Moves in Immuno-Oncology: Astellas' Latest Bet You hear 'immuno-oncology,' you think breakthrough, right? Well, friends, that's what Astellas and Audax Biosciences are shooting for with their fresh handshake over DAX-044. On October 27, 2026, in Tokyo and Melbourne, the two outfits announced they're joining forces to bring this novel immunotherapy to the table. It's...
Continue Reading
A Major Step Forward in AI Infrastructure When two heavyweights clash, you better believe folks are paying attention. OneQode’s deal with AdaniConneX is like a shot across the bow in the AI infrastructure arena. They’re not just dipping a toe in India’s tech waters; they’re diving headfirst with 14 MW of data center muscle right there in Siruseri Sipcot, Chennai....
Continue Reading
A Deep Dive into Lynk Pharmaceuticals' Latest Revelation Lynk Pharmaceuticals just dropped a bombshell with their latest Phase III trial results for zemprocitinib. This selective JAK1 inhibitor seems to be bringing some serious game in the fight against moderate-to-severe rheumatoid arthritis (RA), especially for folks who haven't had much luck with biologics. The drug...
Continue Reading
A New Twist in Illinois: Cash Pop's Arrival Here's something fresh off the press: the Illinois Lottery is now on the ride with Brightstar's Cash Pop. This patented game isn't just another number pick—it's an engaging draw-based game featuring hourly draws with price tags of $1, $2, $5, and $10. It's like clockwork, and trust me, it's more than just the usual spin....
Continue Reading
Etisalat's Stellar Performance: A Deeper Dive When a company like Etisalat drops news of a whopping 46% increase in net profit year-over-year, you sit up and pay attention. Those numbers aren’t just a flash in the pan; they're the result of some serious strategic maneuvers and ripe market conditions. Etisalat isn't resting on its laurels, and their latest financials...
Continue Reading
Amgen's Steady Dividend: A Testament to Stability Diving into the mess that is today's biotech market, Amgen (NASDAQ:AMGN) stands out like a beacon of stability with its recent dividend announcement. The Board's decision to dole out a $2.52 per share dividend for the fourth quarter of 2026 showcases confidence amidst both promising ventures and looming uncertainties....
Continue Reading
A Meeting of Great Minds in Shanghai Alright, listen up. Shanghai's gearing up to be the nerve center for the 2026 World Laureates Forum (WLF), and it's seething with potential. This ain't your regular science fair; it's a lion's den of brainpower set to crack open the future of science and tech. With the heavy-hitters like Nobel and Turing laureates on the docket, you're...
Continue Reading
Dive into Mercado González's Cultural Opening Over in La Habra, Northgate González Market has just flung open the doors to its latest masterpiece: Mercado González. Picture this, a place where the mundanity of grocery shopping melds with a vibrant fiesta of Mexican cuisine, artisanry, and cultural vibes. They transformed an older store into something that commands not...
Continue Reading
Top 5 Most Recently Viewed Articles
Understanding Exelon's Upcoming Earnings Report Exelon Corporation (NASDAQ: EXC) is preparing to reveal its quarterly earnings in the near future. Investors are keenly awaiting the results, as they want insights into the company’s performance and projections for the following period. Analysts predict that Exelon will report an earnings per share (EPS) of $0.39,...
Continue Reading
Vallourec Invites Warrant Holders to General Meeting Vallourec has announced a significant upcoming event for its warrant holders, also known as BSA. This meeting is set to take place soon, providing an opportunity for holders to engage with the company's future decisions. Details of the Meeting The general meeting will occur at the Vallourec headquarters, where the...
Continue Reading
Pomerantz LLP Begins Investigation on Behalf of Molina Investors Pomerantz LLP has embarked on an investigation focusing on the interests of investors in Molina Healthcare, Inc. (NYSE: MOH). This inquiry aims to ascertain whether Molina and certain executives may have been involved in any unlawful activities related to securities fraud. Key Financial Findings and Investor...
Continue Reading
Unlocking E-commerce Potential in Grocery Retail In a transformative announcement, SymphonyAI, a leader in predictive and generative AI SaaS products for enterprises, has unveiled groundbreaking insights from its annual grocery e-commerce study. This research indicates a noteworthy 8% growth opportunity for retailers leveraging AI-driven strategies in their connected...
Continue Reading
Honda and Nissan's Strategic Talks Honda (NYSE:HMC) and Nissan (OTC:NSANY) have entered discussions that may lead to a potential merger, a significant move reflecting the shifting landscape of Japan's automotive industry. As these two giants explore deeper ties, it marks a notable strategy to face the competition posed by Tesla and various Chinese car manufacturers....
Continue Reading